Skip to main content

View full-text article in PMC

. 2017 Oct 31;7:14421. doi: 10.1038/s41598-017-15007-2

Table 1.

SOF and/or LDV regimens evaluated in the BelloCell System against a genotype 1b HCV replicon cell line.

	[Sofosbuvir] (ng/ml)^a
[Ledipasvir] (pg/ml)^a	0	EC_25-SOF	EC_50-SOF	EC_95-SOF
	EC_25-LDV	EC_25-LDVEC_25-SOF	EC_25-LDVEC_50-SOF	EC_25-LDVEC_95-SOF
	EC_50-LDV	EC_50-LDVEC_25-SOF	EC_50-LDVEC_50-SOF	EC_50-LDVEC_95-SOF
	EC_95-LDV	EC_95-LDVEC_25-SOF	EC_95-LDVEC_50-SOF	EC_95-LDVEC_95-SOF

^aConcentrations were determined using a 96-well plate drug screening assay.